RCC patients with an increased plasma CCL17/CCL22 ratio had decreased overall survival [114], and patients with increased expression of the receptor for these cytokines (CCR4) had worse overall survival in multiple tumor types [118,119], including RCC [120]. The gene discussed is CCL22; the disease is neoplasm.